Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 6:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 445 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Amyotrophic Lateral Sclerosis Clear all
Completed No phase listed Observational

The E-health Application To Modify ORal Energy Intake and Measure Outcomes REmotely in ALS Clinical Trial (EAT MORE2)

NCT04051333
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
ALS Nutrition App (MyDataHelps platform)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Early Phase 1 Interventional

SSRIs vs. TCAs for Depression in ALS Patients

NCT02851914
View directory record Official record
Conditions
Depression, Amyotrophic Lateral Sclerosis
Interventions
Tricyclic Antidepressants ("TCA"), Selective Serotonin Uptake Inhibitors ("SSRI")
Drug
Lead sponsor
St. Louis University
Other
Eligibility
25 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Jun 7, 2026, 6:20 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Biospecimen Biorepository for the Study of ALS, ALS-FTD and Similar Neurodegenerative Disorders

NCT05116943
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2030
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Jun 7, 2026, 6:20 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

NCT05053035
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AL001, Placebo
Drug
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Tampa, Florida • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)

NCT01083667
View directory record Official record
Conditions
Familial Amyotrophic Lateral Sclerosis
Interventions
Pyrimethamine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2017 · Synced Jun 7, 2026, 6:20 AM EDT
Recruiting Phase 2 Interventional

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

NCT07002034
View directory record Official record
Conditions
Adjustment Disorder
Interventions
RE104 for Injection
Drug
Lead sponsor
Reunion Neuroscience Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
30
States / cities
Birmingham, Alabama • Tucson, Arizona • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 7, 2026, 6:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Environmental Exposure and Neurological Diseases Questionnaire

NCT02916966
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Patient Registry
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
460 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Jun 7, 2026, 6:20 AM EDT
Terminated Phase 2 Interventional

A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.

NCT03196375
View directory record Official record
Conditions
Motor Neuron Disease
Interventions
FLX-787-ODT (orally disintegrating tablet), Placebo ODT
Drug
Lead sponsor
Flex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Scottsdale, Arizona • Sacramento, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Jun 7, 2026, 6:20 AM EDT
Completed No phase listed Observational Results available

DESIPHER_Speech Degradation as an Indicator of Physiological Degeneration in ALS

NCT02675075
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Not applicable Interventional

A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS

NCT03324399
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS
Interventions
probiotic
Dietary Supplement
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Jun 7, 2026, 6:20 AM EDT
Not listed Phase 3 Interventional

Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis

NCT00069186
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Creatine Monohydrate
Drug
Lead sponsor
The Avicena Group
Industry
Eligibility
21 Years to 80 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
8
States / cities
San Francisco, California • Kansas City, Kansas • Albuquerque, New Mexico + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 2 Interventional Results available

Mexiletine in Sporadic Amyotrophic Lateral Sclerosis

NCT02781454
View directory record Official record
Conditions
Sporadic Amyotrophic Lateral Sclerosis
Interventions
Mexiletine, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Phoenix, Arizona • Orange, California • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 2 Interventional Results available

A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT00790582
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
lithium carbonate
Drug
Lead sponsor
Forbes Norris MDA/ALS Research Center
Other
Eligibility
21 Years to 80 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Jun 7, 2026, 6:20 AM EDT
Withdrawn Phase 2 Interventional

Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis

NCT03457753
View directory record Official record
Conditions
ALS
Interventions
Riluzole Oral Soluble Film
Drug
Lead sponsor
Aquestive Therapeutics
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2019 · Synced Jun 7, 2026, 6:20 AM EDT
Suspended Phase 1 Interventional

Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis

NCT01082653
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
autologous bone marrow-derived stem cells
Biological
Lead sponsor
TCA Cellular Therapy
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Covington, Louisiana
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT03160898
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Reldesemtiv, Placebo
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 80 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
47
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Jun 7, 2026, 6:20 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Examining Interactions Between PALS and Caregivers

NCT06819124
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Structured Communicative Interaction, Unstructured communicative interaction
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 90 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Trial of Ezogabine (Retigabine) in ALS Subjects

NCT02450552
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Ezogabine, Placebo
Drug
Lead sponsor
Brian Wainger
Other
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jun 7, 2026, 6:20 AM EDT
Recruiting Not applicable Interventional

Investigation on the Cortical Communication (CortiCom) System

NCT03567213
View directory record Official record
Conditions
Tetraplegia, Locked-in Syndrome, Brainstem Stroke, Amyotrophic Lateral Sclerosis
Interventions
Surgical implantation of CortiCom system
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
22 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Jun 7, 2026, 6:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cortex Changes in Real/Imagined Movements in Amyotrophic Lateral Sclerosis (ALS)

NCT00809224
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 2 Interventional Results available

Multiple Doses of AT-1501-A201 in Adults With ALS

NCT04322149
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AT-1501
Drug
Lead sponsor
Anelixis Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Jun 7, 2026, 6:20 AM EDT
Terminated Phase 3 Interventional Results available

Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension

NCT03948178
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Levosimendan
Drug
Lead sponsor
Orion Corporation, Orion Pharma
Industry
Eligibility
18 Years to 120 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Phoenix, Arizona • La Jolla, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS

NCT00573443
View directory record Official record
Conditions
Pseudobulbar Affect (PBA)
Interventions
dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg, Placebo
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
45
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 2 Interventional Results available

Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT02460679
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
EPI-589
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
21 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Jun 7, 2026, 6:20 AM EDT